The HL therapy market—currently dominated by multidrug chemotherapy regimens—will experience significant growth over the 2015-2025 forecast. This growth will be fueled by the label expansion of Adcetris and the approval of two immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab).

Table of contents

  • Disease Landscape & Forecast
    • Executive Summary
      • Introduction
        • Key Findings
    • Commercial Outlook
      • Market Outlook
        • Key Findings
        • Expert Insight
        • Market Overview
      • Drivers and Constraints
        • What Factors Are Driving the Market for Hodgkin's Lymphoma?
        • What Factors Are Constraining the Market for Hodgkin's Lymphoma?
      • Drug-Class-Specific Trends
        • Immune Checkpoint Inhibitors
        • Monoclonal Antibodies/Antibody-Drug Conjugates
    • Forecast
    • Etiology and Pathophysiology
      • Etiology and Pathophysiology
        • Key Findings
        • Disease Overview
      • Etiology
      • Pathophysiology
      • Classification of Hodgkin's Lymphoma
      • Risk Assessment and Staging of Hodgkin's Lymphoma
      • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Introduction
        • Key Findings
        • Expert Insights
        • Overview
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution of Hodgkin's Lymphoma
        • Classical Hodgkin's Lymphoma, by Histological Subtype
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment Overview
      • Introduction
        • Key Findings
        • Expert Insight
        • Treatment Overview
      • Diagnosis
        • Treatment Providers and Referral Patterns
      • Treatment Goals
        • Key Physician Insights on Clinical End Points
      • Key Current Therapies
        • Overview
        • Chemotherapies
        • Monoclonal Antibodies/Antibody-Drug Conjugates
      • Medical Practice
        • Drug-Treatable Population
        • Treatment Guidelines
        • Region-Specific Treatment
    • Unmet Need Overview
      • Introduction
        • Key Findings
        • Expert Insight
      • Attainment of Unmet Needs
        • Current Attainment of Unmet Needs in Hodgkin's Lymphoma
        • Future Attainment of Unmet Needs in Hodgkin's Lymphoma
    • Emerging Therapies Overview
      • Introduction
        • Key Findings
        • Expert Insight
        • Pipeline Overview
      • Late-Phase Pipeline Analysis
        • Notable Developments in the Late-Phase Pipeline for Hodgkin's Lymphoma
      • Orphan Drug Designation
        • Orphan Drug Provisions: United States
        • Orphan Drug Provisions: Europe
      • Key Emerging Therapies
        • Immune Checkpoint Inhibitors
        • HDAC Inhibitors
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Hodgkin's Lymphoma
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
      • U.S. Reimbursement Dynamics
        • Reimbursement Dynamics in Hodgkin's Lymphoma in the United States: Current and Future
    • Methodology
      • Methodology
        • Bottom-Up Market Forecasting Overview
        • Patient Share and Sales Calculations
        • Drug-Treatment Rate Assumptions
        • Patient Share Assumptions
        • General Sources of Data
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • [Optional] Biosimilar Erosion
        • Price per Cycle and Course Assumptions, 2015
        • Price per Cycle and Course Assumptions, 2025
    • Appendix
      • Experts Interviewed
      • Hodgkin's Lymphoma Bibliography

Author(s): Dana Gheorghe

Dana Gheorghe, is a senior business insights analyst on the Oncology team at Decision Resources Group, specializing in non-Hodgkin’s lymphoma and renal cell carcinoma, with expertise in multiple myeloma and metastatic colorectal cancer. Her previous experience includes postdoctoral positions at Imperial College London and the Marie Curie Research Institute. Dr. Gheorghe holds a in cellular biology and biochemistry from the University of Sheffield and a in Molecular Biology from the University of Edinburgh.


Related Reports

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Landscape & Forecast | Disease Landscape & Forecast

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over th...

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2019

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | Detailed, Expanded Analysis: Relapsed or refractory DLBCL - (US-EU)

MARKET OUTLOOK Relapsed/refractory diffuse large B-cell lymphoma (R/R

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Epidemiology | Mature Markets Non-Hodgkin's Lymphoma

DRG Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) comprises epidemiological estimat...

View Details